For more information, visit https://diadembio.com/

Halloran Consulting Group, a ProductLifeGroup company, is a life science consulting firm that provides strategic regulatory, quality, clinical, and organizational support in the pharmaceutical, biotechnology, and medical device sectors in the United States. As trusted industry partners we offer expertise in operational excellence, fostering innovation across the life sciences ecosystem. For more information, please visit https://hallorancg.com/

OncoC4, Inc. is a private clinical-stage biopharmaceutical company located in Rockville, MD. Targeting innate and adaptive immune checkpoints to treat cancer and neurodegeneration, OncoC4 actively engages in the discovery and development of novel biologicals by combining an in-depth understanding of immunology with unique designs. For more information, please visit https://oncoc4.com/

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhyloCode™ Panels and Photocycle®, Phen Imager® Fusion, and Phen Imager HT Instruments. For more information, visit https://www.akoyabio.com/

Company description: At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our exome and genome tests translate complex genomic data into clinical answers. It all starts with a single test. for more information, please visit https://www.genedx.com

Vicero is a preclinical biopharmaceutical company pioneering the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology. The VINCOBODY product engine is proprietary VHH modular technology that enables Vicero to build best in class IO and ADC therapeutics with the potential to address unmet need in the immuno-oncology solid tumor market. Our team of experienced scientists and drug developers has delivered more than 20 life extending therapies to patients in need. For more information, please visit us at www.vicerobio.com or our LinkedIn page

For more information please visit https://www.bionanopharma.com/

Since 2008, we at i-Pharm have specialized in life sciences recruitment, supporting Pharmaceutical, Biotech, MedTech and CRO companies globally. With offices in major hubs, we deliver high-quality recruitment solutions, focusing on Medical Affairs, Clinical Development, Clinical Operations, Regulatory Strategy, CMC, and Commercial sectors, driven by strong values and industry expertise. For more information, please visit https://www.i-pharmconsulting.com/

Delivering the power of T cells to cancer patients. For more information, visit https://immatics.com/

For more information please visit https://www.novel.care/

Coherus is a commercial-stage innovative oncology company with a US FDA approved PD-1 inhibitor, LOQTORZI, as well as two proprietary pipeline products; a first in class Phase 2 anti-IL-27, casdozokitug, being developed in combination with LOQTORZI for the treatment of liver and lung cancer and a highly selective cytolytic CCR8 antibody, CHS-114, being developed in combination with LOQTORZI in head and neck squamous cell carcinoma and gastric cancer. Clinical data readouts are occurring in 2025 supporting these studies with safety, initial efficacy and proof of mechanism that builds momentum with initial key data readouts for these studies being projected to occur in H1 2026.LOQTORZI is the only FDA-approved treatment for metastatic/recurrent locally advanced nasopharyngeal carcinoma in all lines of therapy and the new standard of care. LOQTORZI was launched in the U.S. in Q1 2024 and is expected to reach $150M to $200M in sales within three to four years.In addition, LOQTORZI is being evaluated in two pivotal clinical trials, which could expand the label into additional indications in the U.S.. The first is in combination with anti-BTLA, tifcemalimab, in small cell lung cancer sponsored by Junshi BioSciences and the second is planned to open in the 2H of 2025 in combination with INO-3112 in locally advanced high-risk HPV positive head and neck cancer.Coherus is focused on expanding the indications for LOQTORZI in combination with other agents to extend patient survival across tumor types. The market opportunity addressed by current pipeline candidates is up to $15B annually. For more information please visit https://www.coherus.com/.

Rivia is an integrated trial monitoring platform with AI-driven analytics, designed for clinical teams and medical leadership. It unifies data across vendors in days, enabling earlier interpretation and effective action on trial data. Sponsors like Alentis and Altrubio monitor patients and generate reports in minutes, unlocking the full potential of their therapies. For more information, please visit rivia.com